Aims: To examine the effects of a high-fat-diet (HFD) on monogenic neonatal diabetes, without the confounding effects of compensatory hyperinsulinaemia.
| INTRODUCTION
Diabetes is a major and growing public health problem, and over the past two decades obesity has also substantially risen worldwide. Type 2 diabetes occurs when insulin-secreting β cells fail to adequately respond to the increased demand in the presence of insulin resistance. 1, 2 In both humans and experimental animal models, obesity is a leading pathogenic factor for developing insulin resistance and diabetes. 3 In animal models, β-cell failure can be accelerated or delayed by dietary modifications, therefore understanding the in vivo contribution of high glucose (glucotoxicity) and lipids (lipotoxicity) to β-cell failure is crucial. Many studies have shown that a high-fat diet (HFD)
accelerates diabetes, supporting the concept of lipotoxicity and development of insulin resistance; however, the diabetogenic effect of reduced insulin sensitivity vs the glucotoxic effect of hyperglycaemia cannot entirely be ruled out. While several mouse models of diabetes have been used to study the contribution of an HFD and obesity, the role of an HFD in insulin-secretory-deficient monogenic diabetes remains elusive.
Gain-of-function (GOF) mutations in the ATP-sensitive K + (K ATP ) channel have been identified as the main cause of human neonatal diabetes 4 because of the inability of β cells to secrete insulin. 5 We previously generated a mouse model of human neonatal diabetes by introducing a K ATP -GOF mutation into the rosa26 locus under the Cre recombinase control. 6 As expected, and mimicking the human disease, mice expressing the K ATP -GOF mutation specifically in pancreatic β cells do not secrete insulin in response to glucose and rapidly develop severe diabetes. 6 These mice show normal islet architecture in early stages of diabetes; however, as diabetes progresses, they demonstrate a marked loss of islet insulin content and β-cell mass, 6, 7 which are classic findings in other forms of diabetes as well. [8] [9] [10] Critically, we have shown that loss of β-cell mass in these mice is not attributable to β-cell death, as frequently assumed, but instead to loss of β-cell identity. 7 Comorbidity of hyperglycaemia and elevated free fatty acids (glucolipotoxicity) is also critical in the pathogenesis of diabetes 11 ; however, little is known about the underlying mechanisms at the level of the β-cell ion channel, electrical activity, Ca 2+ homeostasis and exocytosis. To test the contribution of elevated lipids in insulin-secretorydeficient monogenic diabetes, K ATP -GOF mice were exposed to an HFD. Surprisingly, K ATP -GOF mice demonstrated resistance to HFDinduced obesity and markedly divergent blood glucose control, with some K ATP -GOF mice demonstrating persistent severe diabetes and others remission of diabetes. In remitting mice, islet insulin content and β-cell mass was maintained, and remission was preceded by improved insulin sensitivity and increased circulating plasma insulin and glucagon-like peptide-1 (GLP-1). Together, these results show that restriction of dietary carbohydrates and caloric replacement by fat induces metabolic changes at the cellular and whole-body level that are beneficial in terms of decreasing glucotoxicity in insulinsecretory-deficient diabetes.
| MATERIALS AND METHODS

| Animals and diets
Animal studies were performed in accordance with protocols approved by the Washington University Animal Care Committee. The mice were housed in standard 12-hour light/12-hour dark circadianclock conditions. Tamoxifen-inducible β-cell-specific K ATP -GOF transgenic mice were previously generated. 6 Tamoxifen (50 μg/g body weight) was given for 5 days to 9-to 10-week-old mice to promote transgene expression. 6 Single-transgenic, Pdx-Cre
, and wild-type littermates were used as controls. 6 To test the effect of the HFD, K ATP -GOF and control littermate mice were randomly divided into two groups: one fed with a normal chow diet and one fed with an HFD initiated at the same time as tamoxifen. Four independent batches of HFD (45% fat; Teklad Harlan, Indianapolis, Indiana) were used throughout the experiments. Blood glucose was measured in tail vein samples using a Contour blood glucose meter (Bayer Healthcare, Tarrytown, New York).
| Glucose and insulin tolerance tests
Blood glucose was measured in tail vein samples before (time 0) and after intraperitoneal injection of either 1. 
| Haematoxylin and eosin staining and immunohistochemistry
The HFD-fed mice were killed 130 days after tamoxifen injection.
Pancreases were fixed and paraffin-embedded for sectioning. Serial 5-μm sections and haematoxylin and eosin staining was carried out at the Anatomic/Molecular Pathology Core, Washington University.
Immunohistochemistry was carried out as previously described, 7 stained with guinea pig anti-insulin 2.7 | Pancreatic islet isolation, total insulin content and glucose-stimulated insulin secretion
Islet isolation was performed as previously described. 6 All visible islets were manually handpicked using a dissecting microscope, and maintained overnight in CMRL-1066 (5.6 mM glucose) medium (Gibco Inc.,
Waltham, Massachusetts) supplemented with 10% fetal calf serum, 100 U/mL penicillin and 100 μg/mL streptomycin. 7 Total insulin was extracted from islets in 0.2 N/85% acid-ethanol and measured using a rat/mouse insulin ELISA kit (Crystal-Chem Inc., Elk Grove Village, Illinois). Islets (10 per well) were pre-incubated in glucose-free CMRL-1066 plus 3 mM glucose for 1 hour, and then incubated at 37 C in CMRL-1066 plus 3 or 23 mM glucose, or 30 mM KCl for 1 hour. The medium was then removed and insulin release was measured using a rat insulin radioimmunoassay (Millipore, St Charles, Missouri). 
| Glycogen content
| Statistical methods
Data are presented as mean AE SEM. Differences between two groups were tested using t tests and differences among several groups were tested using analysis of variance (ANOVA) and a post hoc Tukey's test, assuming that the data were normally distributed for each variable. Significant differences among groups (P < 0.05, P < 0.01, P < 0.001 and P < 0.0001) are shown, while non-significant differences are not shown.
3 | RESULTS
| Resistance to HFD-induced obesity and remission of diabetes in K ATP -GOF mice
After tamoxifen injection, β-cell-specific K ATP -GOF mice 6 demonstrated a marked increase in blood glucose levels and became severely diabetic ( Figure 1A ). 6, 13 As diabetes progressed, K ATP -GOF mice showed a marked decrease in islet insulin content and β-cell mass, secondary to chronic hyperglycaemia (glucotoxicity). To test the contribution of lipids in addition to chronic hyperglycaemia (glucolipotixicity), insulin-secretion-deficient K ATP -GOF mice were exposed to an HFD. As expected, K ATP -GOF mice had increased blood glucose levels because of the inability to secrete insulin in response to glucose; however, they progressed to a markedly divergent phenotype over time.
While some HFD-fed K ATP -GOF mice developed severe diabetes Figure 1B] ). Importantly, K ATP -GOF-R and K ATP -GOF-NR mice appeared within the same cohorts and also among K ATP -GOF littermates. K ATP -GOF mice fed a chow diet showed a slight decrease in body weight over time compared with control mice ( Figure 1C ). As expected, HFD-fed control mice showed increased body weight over time. Surprisingly, HFD-fed K ATP -GOF mice did not exhibit weight gain ( Figure 1D ) and had similar weights to chow diet-fed K ATP -GOF mice. Although all HFD-fed control mice had a marked increase in body weight, males were significantly heavier than females, but these sex differences were not present in the K ATP -GOF mice.
| Improved insulin sensitivity in K ATP -GOF-R mice precedes the lowering of blood glucose and diabetes remission on the HFD
In addition to diabetes remission, K ATP -GOF-R mice had lower fasting blood glucose levels and improved glucose tolerance at 100 days after tamoxifen injection compared with K ATP -GOF-NR mice (Figure 2A ,B).
Moreover, K ATP -GOF-R mice showed a marked improvement in insulin sensitivity at day 21 of HFD feeding, compared with the insulinresistant K ATP -GOF-NR mice ( Figure 2C ). It is important to note that the improvement in insulin sensitivity preceded the lowering of blood glucose in K ATP -GOF-R mice, and was maintained over a period of 120 days ( Figure 2D ).
| Increased plasma insulin and GLP-1 concentrations in HFD-fed K ATP -GOF-R mice
As previously demonstrated, 6 chow diet-fed K ATP -GOF mice showed a marked (80%) reduction in plasma insulin compared with control littermates; however, HFD-fed K ATP -GOF mice exhibited a different pattern. Circulating plasma insulin was reduced in both K ATP -GOF-NR and K ATP -GOF-R mice at 22 days; however, at 110 days, HFD-fed K ATP -GOF-R mice showed an increase in plasma insulin similar to that in control mice, whereas plasma insulin was reduced over time in K ATP -GOF-NR mice (Table 1 ). There was a transient increase in plasma glucagon concentration only in HFD fed K ATP -GOF-R mice at 22 days, values that decreased to normal control levels at 110 days (Table 1) .
On day 22, there were no significant differences in leptin or GLP-1 concentrations in controls, K ATP -GOF-NR or K ATP -GOF-R mice. At 110 days, leptin was significantly lower in both K ATP -GOF-NR and K ATP -GOF-R mice, and GLP-1 level was markedly increased only in HFD-fed K ATP -GOF-R mice (Table 1) .
3.4 | HFD prevents loss of whole-body fat mass and bone mineral density in K ATP -GOF-R mice
Chow diet-fed K ATP -GOF diabetic mice showed a marked reduction in body fat mass (18.24%) compared with control littermates (27.37%), and had severe bone abnormalities, including scoliosis ( Figure 3A ).
HFD-fed K ATP -GOF-NR mice had similar loss of fat and bone mass to chow diet-fed K ATP -GOF mice but, strikingly, K ATP -GOF-R mice maintained similar body composition to that of HFD-fed control mice ( Figure 3B ). Correlating with this, MRI showed a marked reduction in whole-body fat mass in K ATP -GOF-NR diabetic mice, but not in K ATP -GOF-R mice ( Figure 3C ). It is important to note that whole-body lean mass was similar in the three groups ( Figure 3C ).
Plasma triglyceride, cholesterol and free-fatty acid concentrations were markedly increased in HFD-fed K ATP -GOF-NR mice but decreased to HFD-fed control levels in K ATP -GOF-R mice ( Figure 3D ).
3.5 | Food intake was significantly increased and physical activity markedly impaired in K ATP -GOF-NR mice, but was normal in K ATP -GOF-R mice
Mice fed with both a chow diet and an HFD for 135 days were subjected to metabolic cage measurements for 72 hours. There were no significant differences in food intake or physical activity between chow diet-fed control mice and chow diet-fed K ATP -GOF mice during the day (6:00 AM to 6:00 PM); however, at night (6:00 PM to 6:00 AM)
K ATP -GOF mice were significantly less active than control mice and showed no significant difference in food intake ( Figure 4A,B) . Importantly, HFD-fed K ATP -GOF-NR diabetic mice showed a significant increase in food intake and a marked decrease in movement compared with both HFD-fed control and K ATP -GOF-R mice at night time ( Figure 4E,F) . The respiratory exchange rate was not significantly different between groups fed the same diet ( Figure 4C,G) ; however, metabolic efficiency was markedly decreased in both chow diet-fed K ATP -GOF mice ( Figure 4D ) and HFD-fed K ATP -GOF-NR diabetic mice ( Figure 4H ). There was a slight improvement in metabolic efficiency in K ATP -GOF-R mice compared with control mice in the same diet group ( Figure 4H ).
| Avoidance of secondary loss of insulin content and β-cell mass in HFD-fed K ATP -GOF-R mice
Since chow diet-fed K ATP -GOF diabetic mice demonstrated a marked decrease in insulin content and β-cell mass, 6 we tested the potential effects of an HFD on pancreatic insulin content. While HFD-fed K ATP -GOF-NR mice showed a similar loss of insulin immunostaining to chow diet-fed K ATP -GOF diabetic mice, HFD-fed K ATP -GOF-R mice demonstrated maintenance of insulin/glucagon immunostaining Figure 5A ). These results correlate well with the total insulin content measurements in isolated islets. While total islet insulin content was markedly reduced in HFD-fed K ATP -GOF-NR mice, it was partially preserved in HFD-fed K ATP -GOF-R mice ( Figure 5B ). As predicted by the mutation, glucose-stimulated insulin secretion was markedly reduced in islets from both HFD-fed K ATP -GOF-R and K ATP -GOF-NR mice compared with control islets. Insulin secretion in response to KCl depolarization was significantly reduced in islets from both K ATP -GOF-R and K ATP -GOF-NR mice compared with controls ( Figure 5C ); however, K ATP -GOF-R islets secreted more insulin than K ATP -GOF-NR islets, presumably because of the marked decrease in insulin content observed in these islets ( Figure 5B ). Strikingly, basal insulin secretion was significantly increased in K ATP -GOF-R islets ( Figure 5C ), but not in K ATP -GOF-NR islets, which is consistent with the elevated plasma insulin demonstrated only in remitter mice (Table 1) . Total liver glycogen content was markedly reduced in HFD-fed K ATP -GOF-NR mice but was normal in K ATP -GOF-R mice ( Figure 5D ).
| DISCUSSION
Progressive deterioration of glucose homeostasis, along with loss of β-cell function and mass are classic findings in several forms of ; however, it is unclear whether altered insulin secretion, hyperinsulinaemia or insulin resistance have significant causal roles in the progression to type 2 diabetes. 17 We have previously shown the development of diabetes in an insulin-secretory-deficient K ATP -GOF mouse model of human neonatal diabetes.
K ATP -GOF mice show a marked loss of insulin content and β-cell mass with the progression of diabetes. These features can be prevented or reverted by lowering blood glucose with either sulphonylureas or insulin therapy. 6, 7, 13 In the present study, we showed that feeding an HFD to K ATP -GOF mice leads to markedly divergent blood glucose control, with 
(D) FIGURE 3 Whole-body composition analysis using dual energy X-ray absorptiometry in A, chow diet-fed and B, high-fat diet (HFD)-fed mice. Bone map, fat map and lean map images were taken for each mouse. The whole-body percentage of fat (fat%) and amount of minerals within bone (bone mineral density [BMD]) are provided above each mouse image. C, Analysis of percentage body fat and lean mass from MRI on HFDfed control (grey), K ATP channel gain-of-function non-remitter (K ATP -GOF-NR; pink) and K ATP channel gain-of-function remitter (K ATP -GOF-R; blue) mice. Values represent mean + SEM; ****P < 0.0001; n = 3-10. D, Plasma lipids (triglycerides, cholesterol and free fatty acids) from HFD-fed control (grey), K ATP -GOF-NR (pink) and K ATP -GOF-R (blue) mice. Values are mean AE SEM. Significance: **P < 0.01; ***P < 0.001; ****P < 0.0001; n = 4-10 mice that later developed severe insulin resistance compared with those that showed mild insulin resistance even before exposure to HFD. 20 This possibility cannot be ruled out in the present study, although non-induced K ATP -GOF mice did not show any basal differences in insulin sensitivity. Mice with adipocyte-specific insulin receptor knockout are also protected against diet-induced obesity, hyperinsulinaemia, dyslipidaemia and insulin resistance. 21, 22 Together, these results suggest that both insulin secretion and action may play a critical role in resistance to HFD-induced obesity. Reduced insulin secretion and decreased body fat mass was shown in obese human subjects pharmacologically treated with octreotide (somatostatin analogue) or diazoxide (K ATP channel opener). 23, 24 Diazoxide treatment promotes similar effects to having K ATP -GOF mutations, where K ATP channels are maintained in the open state and therefore insulin secretion is prevented. [25] [26] [27] [28] Body weight reflects a balance between food intake and energy consumption; however, dietary recommendations for blood glucose control and their influence on the development and progression of diabetes remain controversial. In the present study, we show that, in contrast to K ATP -GOF-NR mice, K ATP -GOF-R mice exhibit efficient energy control with normal food intake and activity, and therefore better glucose control. We and others have shown that partial or FIGURE 4 Metabolic analysis for chow diet-fed mice: A, food intake, B, physical activity, C, respiratory exchange ratio (RER) and D, metabolic efficiency within 12 hours during the day and at night for control (black) and K ATP -GOF (red) mice. Metabolic analysis for HFD-fed mice: E, food intake, F, physical activity, G, RER and H, metabolic efficiency within 12 hours during day and night for control (grey), K ATP channel gain-offunction non-remitter (K ATP -GOF-NR; pink) and K ATP channel gain-of-function remitter (K ATP -GOF-R; blue) mice. Values are mean AE SEM. Significance: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; n = 4-10 mice complete suppression of β-cell K ATP channels in mice induces insulin secretion, leading to improved glucose tolerance [29] [30] [31] [32] [33] ; however, these mice become glucose-intolerant and under-secrete insulin when fed an HFD. 34 In K ATP knockout mice, the decrease in body weight is associated with depletion of subcutaneous, abdominal and retroperitoneal fat mass, but not visceral fat, 35 suggesting an altered balance between energy availability and consumption induced by decreased K ATP activity. Similar to the findings observed in ob/ob mice exposed to a ketogenic diet, 36 K ATP -GOF-R mice maintained adipose tissue and nutrient balance, without increases in plasma lipids. A recent study in a large cohort of patients who were followed for 14 years
showed that high-fat dairy products reduced the risk of developing type 2 diabetes. 37 The conclusions in that study may correlate with our results that an HFD could prevent loss of insulin content and β-cell mass in K ATP -GOF-R mice. Similarly, inhibition of diabetes progression was found in a rat model of type 2 diabetes in which an HFD containing 62% fat was used. 38 The increase in total liver glycogen content in K ATP -GOF-R mice may account for the decrease in food intake and reversion of hyperglycaemia, as this phenomenon has been reported in other diabetic mouse models. 39 Together, these results 
Liver Glycogen ( mol/g) FIGURE 5 A, Representative images of pancreatic paraffin sections stained for haematoxylin and eosin (H&E; left panel) and double-stained for insulin (green)/glucagon (red; middle and right panels). B, Total insulin content per 10 islets. C, Basal insulin secretion at non-stimulatory (3 mM) glucose (left), and fold over basal glucose (23 mM) and KCl stimulated insulin secretion (right) per 10 islets in 1 hour. D, Liver glycogen content per gram of tissue. HFD-fed control (grey), K ATP -GOF-NR (pink) and K ATP -GOF-R (blue) mice. Values are mean AE SEM. Significance: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; n = 3-10 mice suggest that an HFD might be protective in certain forms of diabetes.
Moreover, the observed resistance to HFD-induced obesity in K ATPknockout 35 or K ATP -GOF mice in the present study provides a basis for potential anti-obesity treatment involving altered K ATP channels.
In humans, there have been conflicting reports on the effect of an HFD on diabetes, with no clear understanding of the underlying mechanisms. An HFD is known to accelerate the onset and severity of diabetes in some spontaneously occurring diabetes models. 40 It has been proposed that glucotoxic conditions promote internalization of K ATP channels, leading to a decrease in the membrane hyperpolarized state, thereby inducing insulin secretion. 41 Pharmacological inhibition of large conductance K + channels leads to higher action potentials in an HFD, increased Ca +2 currents and insulin secretion. 42, 43 Chow diet-fed K ATP -GOF mice showed loss of β-cell identity and dedifferentiation 7 similar to the dedifferentiation observed in other models 44, 45 ; however, the decrease in insulin content and loss of β-cell mass was prevented in HFD-fed K ATP -GOF-R mice, suggesting that limiting β-cell insulin-secretory response protects from secondary loss of insulin content and β-cell mass.
Collins et al. 46 showed that, whereas short periods of being fed an HFD enhance glucose-stimulated insulin secretion, a long-term HFD results in a decrease in glucose-stimulated insulin secretion. 
